drugset / Trial / NCT07720193
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
Phase 3
Not yet recruiting
280 enrolled
Nanjing Leads Biolabs Co.,Ltd
Peking University Cancer Hospital & Institute · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This trial is a randomized, double-blind, placebo-controlled multicenter phase III clinical study aiming to evaluate the efficacy and safety of LBL-024 compared with placebo in combination with etoposide and cisplatin or carboplatin (EP or EC) for the first-line treatment of advanced EP-NEC patients.
Timeline
- Start
- 2026-08-22
- Primary completion
- 2030-12-22
- Completion
- 2030-12-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LBL-024 | Unknown | — | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Etoposide | Small molecule | — | Intravenous |